Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2017 07:30 ET | Source: MediWound Ltd.

MediWound’s NexoBrid® Highlighted in 43 Presentations at the 17th European Burns Association Congress

YAVNE, Israel, Sept. 06, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe...
September 01, 2017 08:00 ET | Source: MediWound Ltd.

MediWound Successfully Completes Second Cohort of EscharEx® Phase 2 Study

YAVNE, Israel, Sept. 01, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
August 03, 2017 07:00 ET | Source: MediWound Ltd.

MediWound Reports Second Quarter 2017 Financial Results

NexoBrid® sales double in first half of 2017 BARDA upsizes committed funding by additional $32 million, bringing total contract value to up to $132 million of non-dilutive financing Conference call...
July 28, 2017 12:00 ET | Source: MediWound Ltd.

MediWound to Host Second Quarter 2017 Financial Results Conference Call on August 3, 2017 at 8:30 a.m. Eastern Time

YAVNE, Israel, July 28, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn...
July 19, 2017 16:15 ET | Source: MediWound Ltd.

BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid® Indications

YAVNE, Israel, July 19, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn...
June 23, 2017 08:26 ET | Source: MediWound Ltd.

BARDA Gives Notice of Intent to Exercise First Contract Option to Further Fund MediWound’s NexoBrid® Development

YAVNE, Israel, June 23, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn...
June 16, 2017 08:00 ET | Source: MediWound Ltd.

Independent Study in Germany Shows NexoBrid® Reduces Average Burn Treatment Costs by nearly 30% Versus Standard of Care

YAVNE, Israel, June 16, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn...
June 05, 2017 07:00 ET | Source: MediWound Ltd.

MediWound to Present at the Jefferies Global Healthcare Conference

YAVNE, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
June 02, 2017 09:16 ET | Source: MediWound Ltd.

Poster Presentation Highlighting NexoBrid® Awarded “Best Poster” at the 52nd Congress of the Spanish Society of Aesthetic, Plastic and Reconstructive Surgery

YAVNE, Israel, June 02, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
May 18, 2017 08:00 ET | Source: MediWound Ltd.

MediWound Announces Changes to its Board of Directors

YAVNE, Israel, May 18, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...